Metaplastic breast carcinoma (MBC) accounts for 0.2–5% of invasive breast cancers. The majority of MBCs have a triple-negative phenotype, are highly heterogeneous and respond poorly to chemotherapy. Understanding their divergent differentiation and identifying the cell of origin might provide some much-needed insight into this disease.
- Britta Weigelt
- Carey Eberle
- Jorge S. Reis-Filho
